ABOUT THIS SITE
About legitretatrutide
An independent editorial project. One compound. Published trial data, summarized. No clinic, no vendor, no prescription.
What this site is
Legitretatrutide is an independent editorial project that publishes summaries of the peer-reviewed research literature on retatrutide (LY3437943). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The domain name includes "legit" as a reference to the site's editorial stance: plain, citation-supported, non-sensationalized summaries of what the Phase 1b, Phase 2, and ongoing Phase 3 trials have actually measured — not claims about what retatrutide will do for any individual, not vendor marketing, and not speculation framed as certainty.
The "legit" in the domain is editorial framing — a commitment to the published record over hype. It is not a claim that this site operates a clinic or that retatrutide is approved (it is not).
What this site is not
This site is not a telehealth provider, compounding pharmacy, online prescriber, or vendor of retatrutide or any other compound. It does not help users obtain retatrutide. It does not link to vendors.
Retatrutide is an investigational drug in Phase 3 clinical trials. It is not FDA-approved, not available by prescription, and not commercially available as of mid-2026. Any content on this site that references clinical trial doses does so as a statement of how trials were designed — it is not a recommendation for human use.
This site does not employ physicians, pharmacists, nurses, or any clinical staff.
Editorial standards
Every quantitative claim is cited to a numbered reference. The Retatrutide references page carries the full citation list with DOIs and PubMed links.
Sources used: peer-reviewed journal articles (New England Journal of Medicine, Lancet, Nature Medicine, Cell Discovery, Biomolecules, and others), and registered trial records from ClinicalTrials.gov. Review articles are identified as reviews; Phase 2 trial data and Phase 3 interim reports are identified by study phase.
This site does not invent citations. No claim is made that cannot be traced to a source in the references index.